Kimberly Gentile
Chief Tech/Sci/R&D Officer chez BIOHAVEN LTD.
Fortune : 5 M $ au 31/03/2024
Postes actifs de Kimberly Gentile
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - | - |
Portage Pharmaceutical Ltd.
 Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Chief Operating Officer | - | - |
Historique de carrière de Kimberly Gentile
Anciens postes connus de Kimberly Gentile
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Director/Board Member | - | 03/10/2022 |
| Corporate Officer/Principal | 01/02/2014 | 03/10/2022 | |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 01/01/2000 | 01/02/2014 |
| SCIREX Corp. | Corporate Officer/Principal | 01/01/1996 | 01/06/2000 |
Formation de Kimberly Gentile
| Salem State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 4 |
| Canada | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Commercial Services | 3 |
| Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| BIOHAVEN LTD. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| SCIREX Corp. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Portage Pharmaceutical Ltd.
Portage Pharmaceutical Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Juvenescence Ltd., Portage Pharmaceutical Ltd. is a research and developer of biotechnology pharmaceutical drugs. The private company is based in Toronto, Canada. Portage Pharmaceutical was acquired by Juvenescence Ltd. from Portage Biotech, Inc. on March 04, 2021 for $193.25 million. The CEO of the Canadian company is Frank W. Marcoux. | Commercial Services |
- Bourse
- Insiders
- Kimberly Gentile
- Expérience
